|
|
| (13 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Enalapril maleate]] |
| |authorTag={{AZ}}, {{AM}}
| |
| |genericName=Enalaprilat
| |
| |aOrAn=an
| |
| |drugClass=Angiontensin converting enzyme inhibitor
| |
| |indication=[[hypertension]], [[ malignant hypertension]] and adjunct in Kidney imaging when there is underlying [[renovascular hypertension]]
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=[[hyperkalemia]] (1% ), [[nausea]] (1.1% ), [[headache]] (2.9% )
| |
| |blackBoxWarningTitle=USE IN PREGNANCY
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, Enalaprilat Injection, USP should be discontinued as soon as possible.
| |
| |fdaLIADAdult=*Hypertension
| |
| | |
| :* Dosing Information
| |
| | |
| :: Hypertension ( without diuretics): 1.25 mg IV over 5 minutes every 6 hours (MAX 5 mg/dose)
| |
| | |
| :: Hypertension ( with diuretics)
| |
| | |
| ::: Initial: 0.625 mg IV over 5 minutes, may repeated after 1 hour as needed,
| |
| | |
| ::: Maintenance: 1.25 mg IV every 6 hours
| |
| }}
| |